Brain metastasis as exclusion criteria in extensive-stage small cell lung cancer trials: a trend over decades

Abstract

Aim: To investigate the frequencies and trends of brain metastases (BMs) as exclusion criteria in extensive-stage small cell lung cancer (ES-SCLC) trials.

Methods: We conducted a comprehensive search to identify prospective clinical trials in patients with ES-SCLC. PubMed searches were conducted with the key words “small cell lung cancer” and “extensive”. The online archives of 20 oncology journals were also searched. Recent review articles in ES-SCLC were also investigated for additional articles. Eligible studies must have enrolled primarily ES-SCLC and been published in English. Studies involving brain/chest radiation and brain metastasis-specific trials were excluded. Studies were categorized into allowed/undefined, conditional, or complete exclusion of BM.

Results: In total, 491 published studies were identified by PubMed (240), journal websites (198), and review articles (53). Early publication year (1970-1999) and first-line/maintenance setting were associated with higher incidence of complete exclusion of cases with BMs (P < 0.0001 and 0.0233, respectively). Incidence of complete exclusion was 27% in the 1990s, and then decreased to 12% in the 2000s and 8% in the 2010s.

Conclusion: A significant number of ES-SCLC trials continues to exclude patients with BM. Future studies need to ease eligibility regarding BM according to ASCO/Friends recommendations.

Keywords

Brain metastasis / small cell lung cancer / clinical trials

References

[1] National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: cancer of any site. Available from: https://seer.cancer.gov/statfacts/html/all.html [Last accessed on 19 Feb 2020]

[2] Al-Baimani K,Zhang T,Laurie SA.Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?.Curr Oncol2018;25:e291-7 PMCID:PMC6092056

[3] American Society of Clinical Oncology. Two cancer research organizations submit recommendations to FDA aimed at reducing barriers to clinical trial participation. Available from: https://www.asco.org/about-asco/press-center/news-releases/two-cancer-research-organizations-submit-recommendations-fda [Last accessed on 19 Feb 2020]

[4] Lin NU,Tan AR,Rosen O.Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research brain metastases working group..J Clin Oncol2017;35:3760-73

[5] Uldrick TS,Rudek MA,Schwartz K.Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research HIV working group..J Clin Oncol2017;35:3774-80 PMCID:PMC5793223

[6] Lichtman SM,Damiette Smit MA,Thompson MA.Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group..J Clin Oncol2017;35:3753-9

[7] Chute JP,Feigal E,Johnson BE.Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress..J Clin Oncol1999;17:1794-801

[8] Chen TT,Feigal E,Simon R.A model to select chemotherapy regimens for Phase III trials for extensive-stage small-cell lung cancer..J Natl Cancer Inst2000;92:1601-7

[9] Oze I,Kiura K,Takigawa N.Twenty-seven years of Phase III trials for patients with extensive disease small-cell lung cancer: disappointing results..PLoS One2009;4:e7835 PMCID:PMC2773043

[10] Lally BE,Blackstock AW,Perry MC.Small cell lung cancer: have we made any progress over the last 25 years?.Oncologist2007;12:1096-104

[11] Small cell Lung Cancer. NCCN clinical practice guidelines in oncology. Version I.2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf [last accessed on 19 Feb 2020]

[12] Peters S,Shaw AT,Ahn JS.Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer..N Engl J Med2017;377:829-38

[13] Beaver JA,Pazdur R.Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials..N Engl J Med2017;376:1504-5

[14] McCoach CE,Lu X,Camidge DR.A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: a review of the ClinicalTrials.gov trial registry..J Thorac Oncol2016;11:407-13

[15] Horn L,Szczęsna A,Krzakowski M.First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer..N Engl J Med2018;379:2220-9